QPPV.COM KNOWLEDGE ASSESSMENT

Dinutuximab Beta: Mechanism, Clinical Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Dinutuximab Beta: Mechanism, Clinical Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A case report states that a child developed hypotension during treatment but does not state whether treatment used continuous or intermittent infusion. What is the most appropriate pharmacovigilance action?

Assume continuous infusion because it is the more clinically intensive schedule Code the event as anaphylaxis without further investigation Seek the infusion chart and document the actual schedule, timing, rate, support and clinical diagnosis Exclude the case because the administration schedule is missing

Question 2 of 10 Which approach best characterises a neurologic adverse reaction in a dinutuximab beta case?

Use only the broad term 'neuropathy' for every neurologic complaint Document the exact sensory, motor, central, autonomic, visual or other clinician-diagnosed finding, together with onset, examination, competing causes and outcome Assume any pain report represents a central nervous system event Record neurologic findings only if hospitalisation occurred

Question 3 of 10 Why should fever, hypotension, rash or respiratory symptoms not automatically be labelled cytokine-release syndrome?

Dinutuximab beta cannot cause cytokine release These findings may also reflect hypersensitivity, anaphylaxis, infection, capillary leak or other competing diagnoses Cytokine-release syndrome can occur only after five completed courses Only pain is a clinically relevant adverse reaction for this product

Question 4 of 10 Which statement best reflects the relationship between treatment phase and adverse-event interpretation?

The same symptom has the same meaning regardless of when it occurs Symptoms during the first hours of an infusion, between courses and after treatment interruption may represent different clinical processes Only symptoms occurring after the final course are relevant Treatment timing is unnecessary if the product name is known

Question 5 of 10 Which case narrative best supports a clinically useful pharmacovigilance assessment of severe pain?

Child had pain during therapy Severe adverse event occurred; treatment continued During course 2, day 3 of five daily 8-hour infusions, new burning bilateral limb pain began two hours after infusion started, reached a documented 9/10, limited movement, required scheduled and rescue opioids, improved after treatment interruption and recurred during the next infusion Patient received dinutuximab beta and later complained

Question 6 of 10 Why is it important to distinguish continuous infusion from five daily intermittent infusions when evaluating an adverse event?

The two schedules have identical exposure timing, so the distinction is administrative only The schedule determines the relevant exposure window and interpretation of onset, recurrence and infusion-related toxicity Only continuous infusion can cause pain, whereas intermittent infusion cannot The schedule determines whether GD2 is expressed on tumour cells

Question 7 of 10 A patient reports severe burning and shooting pain during an infusion, but no clinician-diagnosed neurologic disorder is documented. How should the report be handled?

Automatically code a named peripheral neuropathy syndrome Record the reported pain and its characteristics without inferring a specific nerve disorder Ignore the pain because it is an expected effect Record only opioid use and omit the pain event

Question 8 of 10 A report mentions 'blurred vision' but contains no examination or specialist diagnosis. What is the most appropriate approach?

Infer a named ocular or neurologic syndrome Record the visual symptom as reported and seek laterality, acuity or field findings, examination and specialist assessment Treat it as evidence of anaphylaxis Exclude the symptom because it is unrelated to pharmacovigilance

Question 9 of 10 Why must interleukin-2 exposure be separately recorded in relevant dinutuximab beta cases?

It determines whether GD2 is present on the tumour It is a clinically relevant concomitant exposure that may modify interpretation of pain, infusion reactions and systemic toxicity It replaces the need to document the dinutuximab beta infusion schedule It proves that all subsequent adverse events are caused by interleukin-2

Question 10 of 10 Which patient scenario is most consistent with the authorised treatment setting described in the article?

An adult with untreated low-risk neuroblastoma and no prior systemic therapy A child aged 10 months with stable disease after surgery alone A patient aged 12 months or older with high-risk neuroblastoma responding at least partially to induction chemotherapy, followed by myeloablative therapy and stem-cell transplantation Any patient with progressive neuroblastoma, regardless of whether progression has been stabilised

Dinutuximab Beta: Mechanism, Clinical Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings